NCT01316692终止2 期
A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients With Unresectable Stage III or Stage IV Melanoma Disease
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Overall Response Rate
研究概览
简要总结
RATIONALE: Aurora A kinase inhibitor MLN8237 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well Aurora A kinase inhibitor MLN8237 works in treating patients with unresectable stage III-IV melanoma
Funding Source - FDA OOPD
详细描述
PRIMARY OBJECTIVES:
I. Estimate the degree of clinical benefit based primarily on objective clinical responses with AURKA inhibitor, MLN8237 in patients with metastatic melanoma in a phase II, 2-stage trial for patients with measurable unresectable disease.
SECONDARY OBJECTIVES:
I. Assess the progression-free survival and overall survival for all patients enrolled.
II. Define toxicities due to MLN8237 and characterize their severity both over a short and prolonged duration of administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stage IIIc or IV histologically proven melanoma (confirmed by Vanderbilt pathologists), that is not curable by standard surgery, radiation therapy, or chemotherapy. No available effective therapy (i.e.; therapy known to be curative,). Non-biopsied (resected) tumor sites must be measurable for therapy.
- •Patients on stage 2 of the enrollment must have tumor sites that are easily biopsied and be willing to undergo pre- and post-treatment (around day 8 +/- 3 days) tumor biopsies.
- •Adequate performance status for the study, ECOG 0-1
- •Adequate baseline organ system function, including
- •Absolute neutrophil count (ANC) ≥ 1500 cells/mm3 without growth factor support
- •Hemoglobin ≥ 9.0g/dL (without need for transfusion support within 30 days; growth factor allowed)
- •Platelet count ≥100,000 cells/mm3 without transfusion or growth factor requirement
- •Creatinine < 1.5x institutional upper limit of normal (IULN), and/or an adequate renal function as defined by: Calculated creatinine clearance must be ≥ 40 mL/minute (Cockcroft-Gault).
- •Aspartate and alanine aminotransferase < 2.5 x institutional upper limit of normal (IULN), bilirubin < 1.5x IULN
- •Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for 3 months after the completion of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study and for 3 months after the completion of the study
- •A single regimen of prior chemotherapy for metastatic melanoma is allowed. Patients also may have received other immunotherapy or biologic therapy (including kinase inhibitors, antibodies to checkpoints CTLA4, PD1, PDL1, etc.) for metastatic melanoma and there is a limit of three therapy regimens
- •No prior Aurora kinase inhibitor
- •Completed prior chemotherapy a minimum of 4 weeks previously (6 weeks for BCNU and/or mitomycin C), 4 weeks for prior immune therapy, 6 weeks for antibodies to checkpoints CTLA4, PD1, PDL1, etc, and 2 weeks for targeted agents (i.e. inhibitors of MEK, BRAF, Akt, PI3K, mTORC1/2) or localized radiation therapy. All treatment All treatment related toxicity must have resolved to grade 2 or less or to a baseline level as well.
- •Patients cannot receive concomitant radiation therapy at enrollment. While on protocol limited palliative radiotherapy extending over a small bone marrow field (10%) is allowed.
- •Patients with brain metastases are allowed only if they are off systemic corticosteroids and stable for a minimum of 8 weeks.
- •Patients must be 18 years of age or above and voluntary written informed consent must be obtained before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
- •Subject must be able to take oral medication and to maintain a fast as required before and after MLN8237 administration.
- •Exclusion Criteria
- •Uncontrolled or serious infection
- •Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
- •Patients with thromboembolic disease cannot be on coumadin, but low molecular heparins are allowed.
- •Radiation therapy to more than 25% of the bone marrow. Whole pelvic radiation is considered to be over 25%.
- •Prior allogeneic bone marrow or organ transplantation.
- •Concurrent therapy for cancer.
- •Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
- •Inability to comply with protocol-specified procedures (i.e., treatment, monitoring, or follow-up)
- •Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
- •Patients with GI absorptive problems making it unlikely to absorb study medication or more likely to experience GI toxicities.
- •Patient is HIV-positive and is receiving combination antiretroviral therapy.
- •Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort within 14 days prior to the first dose of MLN8237 and during the study
- •Other serious medical problem that in the view of the investigator makes therapy difficult to comply with or difficult to interpret toxicity
- •If applicable, patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrollment.
- •Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- •Patient has received other investigational drugs with 14 days before enrollment
排除标准
- 未提供
结局指标
主要结局
Overall Response Rate
时间窗: At 18 weeks
If 2 or more of 23 pts show CR/PR in stage 1, then an additional 33 pts will be enrolled in stage 2. If 6 or more of the total 56 pts show CR/PR at 18 weeks, then further clinical trials will be warranted. Per Response Evaluation Criteria in Solid Tumor (RECIST)1.1: Complete response (CR): disappearance of all target lesions. Partial response (PR): \>=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Patients are categorized according to the best response achieved prior to occurrence of progressive disease, where best response hierarchy is CR\>PR\>SD\>PD.
次要结局
- Progression-free Survival(On treatment date to last follow-up, disease progression or death for any reason, up to 5 years)
- Overall Survival(On treatment date to last follow-up or death for any reason, up to 5 years)
- Number of Grade 3 and 4 Study-related Toxicities(at 18 weeks)
研究者
Jeffrey A. Sosman, MD
Professor of Medicine; Director, Melanoma and Tumor Immunotherapy
Vanderbilt-Ingram Cancer Center
研究点 (2)
Loading locations...
相似试验
已完成
1 期
MLN8237 to Treat Children With Relapsed/Refractory Solid TumorsUnspecified Childhood Solid Tumor, Excluding CNSNeuroblastomaNCT02444884Children's Oncology Group54
已完成
1 期
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaRefractory Multiple MyelomaNCT01034553Mayo Clinic26
已完成
2 期
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal CarcinomaOvarian CarcinomaNCT00853307Millennium Pharmaceuticals, Inc.31
已完成
2 期
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's LymphomaBurkitt's LymphomaDiffuse Large B-cell LymphomaT-cell Lymphoma, Excluding Primary Cutaneous T-cell LymphomaTransformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell ComponentMantle Cell LymphomaNCT00807495Millennium Pharmaceuticals, Inc.48
已完成
2 期
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate CancerSmall Cell Prostate CancerNeuroendocrine Prostate CancerProstate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine MarkersNCT01799278Weill Medical College of Cornell University60